The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
about
Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutantsHepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudineClinical utility of entecavir for chronic hepatitis B in Chinese patientsDirect acting antivirals for the treatment of chronic viral hepatitisNucleoside/nucleotide analogues in the treatment of chronic hepatitis BIn vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracilAssociation of preexisting drug-resistance mutations and treatment failure in hepatitis B patientsTwo-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions presentMechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.Clinical pharmacokinetics of alamifovir and its metabolites.Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelinesUnsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutationsHepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B.Management of viral hepatitis B.Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro.Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West AfricaPhenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitroResistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.Inhibition of alpha interferon (IFN-α)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-α.Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay.Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.High-throughput matrix-assisted laser desorption ionization-time of flight mass spectrometry as an alternative approach to monitoring drug resistance of hepatitis B virus.Hepatitis B virus resistance to lamivudine and its clinical implications.Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patientsEntecavir: a potent new antiviral drug for hepatitis B.An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patientsAgents in clinical development for the treatment of chronic hepatitis B.Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B.The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitroCurrent therapies for chronic hepatitis B virus infection.Entecavir for the treatment of chronic hepatitis B.Update on new antivirals under development for the treatment of double-stranded DNA virus infectionsComplications in treating chronic hepatitis B in patients with HIV.Antiviral therapies: focus on hepatitis B reverse transcriptaseClevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo.Adherence to medication is a more important contributor to viral breakthrough in chronic hepatitis B patients treated with entecavir than in those with Lamivudine
P2860
Q24563991-C03C6FFD-FF13-4E2E-9783-63F3DB94F590Q24806372-0CF084AF-AC71-4292-81D4-6FB34F073978Q26830371-51A051BA-2452-4C59-AC43-B886075F1E0CQ27022216-33F15F25-1846-4173-A9E6-5498300ABB73Q27030828-71A6450F-EF23-4292-856F-71B8199FE506Q28345952-634A09F5-C7A5-457B-AD01-8288DE2AC8DEQ28535003-37BA096A-C14A-4D33-974C-A3D8D05AB49AQ33267067-18E98C7D-E439-4C0E-859D-C55F3D979791Q33613714-C2A71C90-7782-4A49-959C-532E7B040A8BQ33770064-1EACC3F5-39FB-4010-92B4-9D1E0B0DB2BDQ33826784-D2A6FCC9-4664-4B05-B7DA-B1B3E3E81ABCQ33855708-08810634-D0A9-481A-BBEE-55BD177EC2C8Q33940140-15532597-9899-4076-B8B3-78D8E59FA541Q33950133-8DEF7630-A302-46D1-BB76-34C7AAA84E76Q33959006-34DB73E2-1849-45AF-B805-D6CC9398FCD1Q34024728-5DD225B5-E879-4D80-9A23-6F9B2B0000F8Q34105204-71155C04-EBC8-4677-B992-B64F84B03C15Q34111234-321A30D8-9350-4A58-B06A-11A7D69CF516Q34112556-9686774A-A39E-492B-8ADC-2030B0FC0021Q34299035-BD31B9C0-18A4-4F04-AC52-D302261A713DQ34305346-691AADCE-CABC-43DE-9C28-4CBBF0409A52Q34382067-0CC73E67-04FB-4452-8DA0-F099A6D35DA3Q34489239-4657ACE5-EC5F-4F0B-9DD1-13F38F7A2669Q34720217-55A3CBD0-96C9-4E74-8099-94C7ADEAC99FQ34809263-6C346846-2C5A-41EA-B6D1-6F4AB02B4EAEQ34997985-6C6CE1B9-51A7-4122-9050-DAC562D084F8Q35007583-12283E56-3516-4262-9643-17036D7085BDQ35085989-B3795EE7-9834-4848-9B67-7B1B0739E271Q35094702-3A79E847-DE95-4D05-9377-69D71E856C16Q35102963-7A9A08C6-0D0B-408D-8880-F3BA0756B6DBQ35185749-211238DC-5892-4C6A-ABFA-F9FBCDFCD6D7Q35567341-9B5F08B6-A373-4318-92C0-1D952576C08CQ35879053-BE658BD9-9C48-4C3C-A55A-63A83E5C0C91Q35917541-2B66E7F2-73DC-4E73-A147-F2130E1D3524Q35964745-44726896-71E0-40B4-B8C9-6AFBC78331FDQ36185647-CC4B13AE-798F-4170-86B6-90C486654A89Q36327100-2A642E6D-01B4-4496-BAF3-9160B1CD0DDBQ36467514-F43E0AC8-B9B5-4108-94DB-56200A7B7E79Q36607389-B3E4C00C-D43A-466A-99F4-F99D12D47155Q36713419-3A0582FB-30F6-47E0-82F4-50779C7E8F9C
P2860
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
The polymerase L528M mutation ...... eplication and drug resistance
@ast
The polymerase L528M mutation ...... eplication and drug resistance
@en
The polymerase L528M mutation ...... eplication and drug resistance
@nl
type
label
The polymerase L528M mutation ...... eplication and drug resistance
@ast
The polymerase L528M mutation ...... eplication and drug resistance
@en
The polymerase L528M mutation ...... eplication and drug resistance
@nl
prefLabel
The polymerase L528M mutation ...... eplication and drug resistance
@ast
The polymerase L528M mutation ...... eplication and drug resistance
@en
The polymerase L528M mutation ...... eplication and drug resistance
@nl
P2093
P2860
P356
P1476
The polymerase L528M mutation ...... eplication and drug resistance
@en
P2093
F J Carrilho
R F Schinazi
Y Shiratori
P2860
P304
P356
10.1172/JCI11100
P407
P577
2001-02-01T00:00:00Z